Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lixte Biotech Hlds (LIXT)

Lixte Biotech Hlds (LIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,941
  • Shares Outstanding, K 11,618
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,010 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.07

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +44.40%
on 04/07/26
3.65 -1.10%
on 04/17/26
+0.60 (+19.93%)
since 03/17/26
3-Month
2.36 +52.97%
on 03/09/26
4.01 -9.98%
on 01/29/26
+0.29 (+8.73%)
since 01/16/26
52-Week
0.64 +464.06%
on 06/18/25
6.26 -42.33%
on 09/12/25
+2.48 (+219.07%)
since 04/17/25

Most Recent Stories

More News
Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain...

LIXT : 3.61 (+12.11%)
LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compound...

LIXT : 3.61 (+12.11%)
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

  -Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE)...

LIXT : 3.61 (+12.11%)
LIXTW : 0.0221 (+4.74%)
Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness...

LIXT : 3.61 (+12.11%)
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and...

LIXT : 3.61 (+12.11%)
LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor,...

LIXT : 3.61 (+12.11%)
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused...

LIXT : 3.61 (+12.11%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for...

LIXT : 3.61 (+12.11%)
Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The...

LIXT : 3.61 (+12.11%)
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core...

LIXT : 3.61 (+12.11%)

Business Summary

Lixte Biotechnology Holdings Inc. is a drug discovery company which uses biomarker technology to identify enzyme targets associated with serious common diseases. The company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents...

See More

Key Turning Points

3rd Resistance Point 4.18
2nd Resistance Point 3.92
1st Resistance Point 3.76
Last Price 3.61
1st Support Level 3.34
2nd Support Level 3.08
3rd Support Level 2.92

See More

52-Week High 6.26
Fibonacci 61.8% 4.11
Last Price 3.61
Fibonacci 50% 3.45
Fibonacci 38.2% 2.79
52-Week Low 0.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.